# Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

> **NCT07571161** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 140 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Donanemab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07571161
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2030-04
- **Final completion:** 2030-04
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07571161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07571161, "Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07571161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*